In the majority of Spinal Muscular Atrophy patients (>95{347d1d850516b847fb13d35e9d84eb7d68ac4f2e99acd242b5b346886954d3d7}), the disease is caused by a homozygous loss of exon 7 of the SMN1 gene. This test allows the detection of deletions or duplication in the SMN1, SMN2 and exon 5 of the NAIP genes in genomic DNA isolated from human samples for the purpose of establishing or confirming a potential cause for and clinical diagnosis of Spinal Muscular Atrophy (SMA). This test can be additionally useful for carrier testing. Furthermore, the assay can be used for SMN2 (and NAIP) copy number determination in SMA patients to help prognosis and for treatment eligibility.
Delivering results in days
Pioneering solutions in genomics testing to save lives
Providing the highest levels of patient privacy and advanced data security
Granting access to a team of expert genetics within our state-of-the-art lab